Rimegepant

Overview

Rimegepant, marketed in the United States as Nurtec ODT and in parts of Europe under the brand name Vydura, is an oral small-molecule antagonist of the calcitonin gene-related peptide (CGRP) receptor. It represents a class of migraine-specific therapeutics known as gepants, which emerged in the late 2010s and early 2020s as a fundamentally new approach to treating one of the most common and disabling neurological conditions worldwide. The U.S. Food and Drug Administration first approved rimegepant in February 2020 for the acute treatment of migraine in adults, with or without aura. In May 2021, the FDA expanded the label to include preventive treatment of episodic migraine — making rimegepant the first and only oral medication approved for both indications under a single formulation. This dual indication has reshaped how clinicians approach migraine management, blurring what has historically been a strict divide between abortive and prophylactic therapies.

Migraine affects roughly one billion people globally and disproportionately impacts women of reproductive age, with peak prevalence in the third and fourth decades of life — precisely the years of greatest professional and family responsibility. The economic burden is enormous, with annual costs in the United States alone estimated in the tens of billions of dollars when direct medical expenses, lost productivity, and presenteeism are accounted for. For decades, the mainstays of acute migraine treatment were nonspecific analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen, followed by the introduction of triptans in the early 1990s. Triptans, while effective for many, are contraindicated in patients with cardiovascular disease because of their vasoconstrictor properties, and a substantial subset of patients either fail to respond to them or cannot tolerate their side effects. Preventive options were equally imperfect, drawn from medications repurposed from other specialties — beta-blockers like propranolol, anticonvulsants like topiramate, tricyclic antidepressants such as amitriptyline, calcium channel blockers, and onabotulinum toxin A injections. Each of these came with tolerability concerns ranging from fatigue and cognitive slowing to weight gain, teratogenicity, sexual dysfunction, and dry mouth. Adherence rates with traditional preventive therapies were notoriously poor, with most patients discontinuing within a year. The gepant class, by contrast, was purpose-built around the molecular biology of migraine and targets a single, well-characterized neuropeptide pathway.

Rimegepant is supplied as a 75 milligram orally disintegrating tablet (ODT) that dissolves on the tongue within seconds without the need for water. This formulation was a deliberate design choice: migraine attacks are frequently accompanied by nausea, vomiting, gastroparesis, and difficulty swallowing, all of which can impair the reliability of conventional tablets. Delayed gastric emptying during migraine — a well-documented phenomenon — can also slow the absorption of swallowed tablets, making the sublingual disintegration of an ODT a meaningful pharmacokinetic advantage. The ODT formulation can also be taken discreetly during the workday or social situations, an advantage many patients describe as transformative compared to injectable or intravenous alternatives. Rimegepant was developed by Biohaven Pharmaceuticals, which was subsequently acquired by Pfizer in 2022 in a transaction that valued the rimegepant franchise at more than eleven billion dollars — a measure of the commercial and clinical significance the drug has assumed.

Mechanism of Action

The molecular pharmacology of rimegepant centers on the CGRP receptor, a heterodimeric complex on the surface of neurons and vascular smooth muscle cells composed of the calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1). The CLR component, on its own, has little binding specificity; it is the obligatory pairing with RAMP1 that creates the high-affinity binding pocket for CGRP. This molecular detail matters clinically because gepants like rimegepant interact precisely at this CLR-RAMP1 interface, producing a selectivity profile that minimizes off-target signaling at the closely related amylin, adrenomedullin, and calcitonin receptor systems.

Calcitonin gene-related peptide itself is a 37-amino-acid neuropeptide produced through alternative splicing of the calcitonin gene. It exists in two isoforms, alpha-CGRP (predominant in the nervous system) and beta-CGRP (predominant in the enteric nervous system). The alpha-CGRP isoform is the principal mediator of migraine pathophysiology. It is densely expressed in the trigeminal ganglion, the dura mater's afferent fibers, and within central pain-processing structures including the trigeminal nucleus caudalis and the thalamus. When released from trigeminal sensory neurons during a migraine attack, CGRP binds to its receptor on adjacent neurons, smooth muscle cells, and mast cells, and triggers a downstream cascade of cyclic AMP elevation, vasodilation, mast cell degranulation, plasma protein extravasation, neurogenic inflammation, and central sensitization within the trigeminal nucleus caudalis. The result is the throbbing, often unilateral pain and the associated photophobia, phonophobia, allodynia, and nausea that define a migraine episode. Direct intravenous infusion of CGRP into migraine-prone individuals reliably triggers migraine-like attacks within hours, providing some of the strongest causal evidence that this neuropeptide is not merely a marker of migraine but an active driver.

Rimegepant binds with high affinity and selectivity to the CGRP receptor, with a sub-nanomolar inhibition constant, competitively displacing endogenous CGRP and preventing the downstream signaling cascade. Unlike triptans, which constrict cranial blood vessels via 5-HT1B receptor activation, rimegepant has no intrinsic vasoconstrictor activity. This is a major clinical advantage because it allows the drug to be used safely in patients with stable cardiovascular disease, prior myocardial infarction, peripheral vascular disease, uncontrolled hypertension, and Raynaud phenomenon — populations in whom triptans are formally contraindicated or cautioned. The molecular size and lipophilicity of rimegepant allow it to be administered orally and to achieve sufficient plasma concentrations to occupy CGRP receptors at both peripheral sites (the trigeminovascular system) and, to a more limited but clinically meaningful extent, central sites of migraine pathophysiology. Whether gepants meaningfully cross the blood-brain barrier remains an area of active investigation, but most evidence supports a peripheral primary site of action that secondarily modulates central sensitization.

Because CGRP signaling participates in both the initiation and the maintenance of a migraine attack, blocking its receptor produces effects that span the acute episode while also reducing the frequency of future attacks when given preventively. This pleiotropic effect underlies the dual indication of rimegepant and distinguishes it from drugs that act only on a single phase of the migraine cycle. The half-life of approximately 11 hours, combined with the persistent receptor blockade that follows binding, helps explain why every-other-day dosing is sufficient to produce a measurable reduction in monthly migraine days. Pharmacodynamic studies have also shown that some patients experience reductions in migraine frequency that persist for weeks after discontinuing rimegepant, raising the intriguing possibility that the drug induces durable changes in central sensitization beyond its immediate receptor occupancy.

FDA-Approved Indications and Off-Label Uses

Rimegepant currently carries two FDA-approved indications in adults: the acute treatment of migraine with or without aura, and the preventive treatment of episodic migraine. Episodic migraine in this context generally refers to fewer than 15 headache days per month. The pivotal acute treatment program included three large, randomized, double-blind, placebo-controlled trials demonstrating that a single 75 milligram dose produced significantly higher rates of pain freedom at two hours and freedom from the most bothersome symptom (typically photophobia, phonophobia, or nausea) at two hours, compared to placebo. The preventive trial randomized roughly seven hundred adults with four to eighteen monthly migraine days to either rimegepant 75 milligrams every other day or placebo for 12 weeks; the rimegepant arm achieved a statistically significant reduction in monthly migraine days, with benefit emerging within the first month of treatment.

The drug has not been formally approved for chronic migraine (15 or more headache days per month for at least three months), though clinical experience and ongoing studies suggest it may also be useful in that population. Patients with cluster headache, hemiplegic migraine, and basilar (migraine with brainstem aura) were excluded from pivotal trials, and rimegepant has not been studied or approved for these conditions. The FDA's approval was notable for several reasons: the dual indication arrived in a relatively short timeframe, the every-other-day preventive schedule was a departure from once-daily dosing conventions, and the orally disintegrating tablet formulation set a new bar for patient convenience in migraine pharmacotherapy.

Emerging evidence and clinician experience also point to a possible role for rimegepant in patients with menstrually related migraine, vestibular migraine, and migraine with prominent aura — though these uses remain off-label. Some headache specialists also consider rimegepant for patients who have failed multiple triptans or who have developed medication-overuse headache, given the drug's apparently low propensity to perpetuate that condition. There is also growing interest in using rimegepant as a transitional or bridging therapy in patients beginning a CGRP monoclonal antibody, providing acute and short-term preventive coverage during the weeks it takes for monoclonal antibodies to reach steady state. Importantly, the lack of vasoconstriction makes rimegepant a reasonable option in older adults and in patients with comorbid cardiovascular disease, where triptan use would be precluded. Real-world data published since approval have generally corroborated the clinical-trial findings, with persistence rates that compare favorably to oral preventive options and tolerability that supports long-term use.

Dosing

For the acute treatment of a migraine attack, the recommended dose of rimegepant is one 75 milligram orally disintegrating tablet taken at the earliest onset of head pain. Patients should not take more than 75 milligrams in any 24-hour period. The drug can be taken at any point during a migraine attack, although taking it early — within the first hour of symptoms — generally produces faster and more complete pain relief.

For preventive treatment of episodic migraine, the dose is 75 milligrams every other day. This every-other-day schedule was developed and validated in the pivotal preventive trial and reflects the drug's pharmacokinetic profile and receptor occupancy. Patients using rimegepant for prevention may also take an additional 75 milligram dose for breakthrough acute attacks on non-dosing days, but the total dose still must not exceed 75 milligrams per 24-hour period.

No dosing adjustment is required in patients with mild or moderate renal impairment. Rimegepant has not been studied in patients with end-stage renal disease (creatinine clearance less than 15 mL/min) and should be avoided in that population. Similarly, no dose adjustment is needed for mild or moderate hepatic impairment (Child-Pugh A and B), but the drug should be avoided in severe hepatic impairment (Child-Pugh C), where exposure is markedly elevated. Pediatric dosing has not been established; rimegepant is approved only for adults 18 years and older.

Administration and Patient Counseling

The orally disintegrating tablet should be placed on or under the tongue, where it dissolves rapidly without water. Patients should be instructed not to push the tablet through the blister pack foil, but rather to peel back the foil with dry hands and remove the intact tablet. The hands must be dry to prevent premature disintegration. Once placed in the mouth, the tablet melts in seconds, allowing absorption to begin without the need for swallowing — an important feature for patients experiencing nausea.

Food does not meaningfully impact the efficacy of rimegepant, though a high-fat meal modestly delays peak plasma concentration. Patients may take it with or without food. Counseling should emphasize that early treatment of a migraine attack tends to be more effective than delayed treatment, but that the drug retains efficacy even when taken later in an attack — a clinically useful property given that patients sometimes hesitate to use abortive medication early in an attack out of fear of running out or developing tolerance. Patients should be advised to track migraine frequency and severity in a diary, both to evaluate preventive efficacy and to determine when prescription refills are needed. A simple headache diary capturing date, duration, severity on a zero-to-ten scale, triggers, associated symptoms, and acute medication used can dramatically improve the clinical conversation at follow-up visits.

Patients should also be counseled on lifestyle factors that complement pharmacotherapy. Regular sleep, consistent meal timing, adequate hydration, stress management, limited caffeine, and avoidance of personal migraine triggers can substantially reduce attack frequency. Rimegepant is most effective when integrated into a comprehensive migraine management plan that also addresses these modifiable factors. Patients should also be informed about reasonable expectations: most preventive trials show roughly a 50% reduction in monthly migraine days in responders, not complete remission. Setting realistic goals — fewer attacks, less severe attacks, fewer days lost to migraine — helps maintain adherence and patient satisfaction.

For patients using rimegepant for prevention, missed doses should be taken as soon as remembered unless it is close to the next scheduled dose, in which case the missed dose should be skipped. Patients should not double up on doses to compensate for a missed one.

Adverse Effects by Frequency

Rimegepant is generally well tolerated, with an adverse event profile that compares favorably to most other migraine medications. The most common adverse effect reported in clinical trials was nausea, which occurred in approximately 2% of patients receiving rimegepant compared to roughly 0.4% on placebo in pooled acute treatment studies. Abdominal pain and indigestion were also reported at low frequencies, generally in the 1-2% range. These gastrointestinal effects are typically mild, transient, and rarely lead to discontinuation. In the preventive trial, where patients received rimegepant every other day for 12 weeks, nausea remained the most frequent adverse event but was reported by less than 3% of participants, and the overall discontinuation rate due to adverse events was similar to placebo.

Less common but still notable adverse effects observed across clinical and post-marketing experience include dizziness, fatigue, and somnolence. These tend to be mild and self-limited. Urinary tract infections were occasionally reported in the preventive program but did not appear to be causally related to the drug. Hair loss and depression have been mentioned in post-marketing surveillance but have not been consistently linked to rimegepant use; their incidence appears similar to background population rates.

More serious adverse effects, though uncommon, primarily involve hypersensitivity reactions. Post-marketing reports have described dyspnea, severe rash, and rare cases of facial swelling, urticaria, and bronchospasm. Notably, hypersensitivity reactions have occurred days after a single dose, meaning patients should be counseled to seek immediate medical attention for any rash, throat tightness, breathing difficulty, or facial swelling — even when these symptoms emerge well after taking the medication. Anaphylaxis is rare but possible. Patients who experience any hypersensitivity reaction should discontinue rimegepant permanently and avoid other gepants until evaluated by an allergist or headache specialist, as cross-reactivity with other gepants is theoretically possible but not well characterized.

Unlike triptans, rimegepant does not appear to cause chest pressure, paresthesia, or the dysphoric feelings sometimes called "triptan sensations." It does not produce sedation, cognitive impairment, or weight gain — features that distinguish it favorably from many preventive options like topiramate (associated with cognitive slowing and paresthesia), amitriptyline (associated with dry mouth, sedation, and weight gain), and propranolol (associated with fatigue, exercise intolerance, and depression). Long-term safety data continue to accumulate, and no signals of cardiovascular, hepatic, or hematologic toxicity have emerged in the years since approval. An open-label long-term safety study following patients for up to 52 weeks confirmed the favorable tolerability profile and did not identify new safety signals.

Drug-Drug, Drug-Food, and Drug-Alcohol Interactions

Rimegepant is metabolized predominantly by the cytochrome P450 3A4 (CYP3A4) enzyme, making it susceptible to clinically relevant interactions with both inhibitors and inducers of this pathway. Strong CYP3A4 inhibitors — including ketoconazole, itraconazole, and clarithromycin — significantly increase rimegepant plasma concentrations and should not be used concurrently. Strong CYP3A4 inducers, including rifampin, phenytoin, carbamazepine, phenobarbital, and the herbal supplement St. John's Wort, lower rimegepant exposure to subtherapeutic levels and likewise should be avoided. Moderate CYP3A4 inhibitors such as fluconazole, diltiazem, verapamil, and erythromycin do not require complete avoidance, but patients should not receive a second 75 milligram dose of rimegepant within 48 hours when these agents are co-administered.

Rimegepant is also a substrate of the efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Inhibitors of these transporters, including cyclosporine, may increase rimegepant exposure and warrant the same 48-hour spacing precaution applied to moderate CYP3A4 inhibitors. The drug itself is not a significant inhibitor of major P450 enzymes at therapeutic doses, meaning rimegepant is unlikely to alter the metabolism of other drugs the patient takes.

There are no clinically significant drug-food interactions beyond the modest delay in absorption caused by a high-fat meal. Grapefruit juice, a known CYP3A4 inhibitor, should be consumed in moderation. Alcohol does not pharmacokinetically interact with rimegepant, but because alcohol is itself a common migraine trigger, patients should be counseled to limit consumption if it precipitates their attacks.

Contraindications, Warnings, and Black Box

Rimegepant has only one absolute contraindication in its product labeling: a history of hypersensitivity to rimegepant or any of its excipients. The drug does not carry a black box warning. The principal warnings in the label center on hypersensitivity reactions, which can be delayed in onset, and on the importance of avoiding concomitant strong CYP3A4 inhibitors and inducers. Rimegepant has not been studied in patients with severe hepatic impairment and should be avoided in this population, and it has not been studied in patients with end-stage renal disease.

Clinicians should also exercise caution when combining rimegepant with monoclonal antibodies targeting the CGRP pathway (such as erenumab, fremanezumab, galcanezumab, or eptinezumab). While such combinations are sometimes used in real-world headache practice, the long-term safety of dual CGRP blockade has not been established in large prospective studies. Most headache specialists view selective combination as reasonable in carefully chosen patients, but routine use of two CGRP-targeting therapies simultaneously is not recommended.

Pregnancy and Lactation

There are limited human data on rimegepant use in pregnancy. Animal studies in rats and rabbits at doses many times the human exposure showed no major teratogenicity, but did reveal some decreases in fetal weight at very high doses in rats. Because migraine itself frequently improves during pregnancy and because the absolute risk-benefit balance of rimegepant in pregnancy is not yet defined, the drug should only be used during pregnancy if the potential benefit clearly justifies the potential risk to the fetus. Women of reproductive potential should discuss contraception and pregnancy planning with their prescriber.

It is not known whether rimegepant is excreted in human breast milk, though limited data suggest excretion is low. The developmental and health benefits of breastfeeding should be weighed against the mother's clinical need for rimegepant and any potential adverse effects on the breastfed infant. In practice, many lactation experts consider rimegepant a relatively low-risk option compared to ergotamines or some preventive medications.

Pharmacokinetics

After oral administration of the 75 milligram ODT, rimegepant is rapidly absorbed, reaching peak plasma concentrations approximately 1.5 hours after dosing. The oral bioavailability is approximately 64%. A high-fat meal delays peak concentration by about one hour and slightly reduces total exposure, but these effects are not clinically meaningful. The drug is highly bound to plasma proteins (approximately 96%) and distributes into a moderate volume.

Metabolism occurs primarily in the liver via CYP3A4, with minor contributions from CYP2C9. Importantly, the majority of rimegepant is excreted as unchanged drug, with relatively little reliance on phase II conjugation pathways. Roughly 78% of an administered dose is recovered in feces (about 42% as unchanged drug) and 24% in urine (about 51% as unchanged drug). The terminal elimination half-life is approximately 11 hours, which supports both once-attack acute dosing and the every-other-day preventive regimen by maintaining receptor occupancy across dosing intervals.

Monitoring Parameters

Monitoring for rimegepant is primarily clinical rather than laboratory-based. There is no requirement for routine blood work, electrocardiograms, or imaging. Clinicians should periodically assess migraine frequency, severity, duration, and functional impact using validated tools such as the Migraine Disability Assessment (MIDAS) questionnaire or simple headache diaries. For patients using rimegepant for prevention, the number of monthly migraine days is the primary efficacy outcome and should be tracked from baseline. Patients should also be queried about any rash, swelling, or breathing changes that could represent delayed hypersensitivity reactions, and about acute medication overuse if they are taking the drug both preventively and as needed.

In patients with known liver disease, periodic monitoring of liver function tests is reasonable, though rimegepant has not been associated with hepatotoxicity in clinical trials. Patients on interacting medications such as moderate CYP3A4 inhibitors should be reminded to inform all of their healthcare providers about their rimegepant use to avoid inadvertent overexposure.

Special Populations

In elderly patients, no formal dose adjustment is required, but data in patients over 65 years are more limited than in younger adults. Geriatric patients often have comorbid cardiovascular disease, polypharmacy, and reduced hepatic and renal function, all of which make rimegepant's lack of vasoconstriction and minimal drug-drug interaction profile particularly attractive. Clinicians should still review the full medication list for CYP3A4 modulators before initiating therapy.

In patients with mild or moderate renal impairment, no dose adjustment is needed. In patients with end-stage renal disease or those on dialysis, the drug has not been studied, and its use is not recommended. In hepatic impairment, mild and moderate disease (Child-Pugh A and B) do not require adjustment, but severe impairment (Child-Pugh C) substantially raises drug exposure and should preclude use. Patients with active liver disease should be evaluated case-by-case.

Pediatric use has not been established. Rimegepant is approved only for adults aged 18 and older, though pediatric trials for adolescents are ongoing and preliminary safety data appear reassuring. In transgender patients, patients on hormone therapy, and patients with comorbid mood disorders, no specific dose adjustments are warranted, but clinicians should be mindful that migraine frequency can be influenced by hormonal cycles and psychiatric comorbidity. Patients with major depression, anxiety disorders, or post-traumatic stress disorder frequently have higher migraine burden, and rimegepant's lack of central nervous system depressant effects can make it an attractive option when sedating preventives would worsen psychiatric symptoms.

Obese patients and patients with eating disorders represent another population that benefits from rimegepant's neutral metabolic profile. Topiramate causes weight loss, which can be problematic in patients with restrictive eating patterns; amitriptyline causes weight gain, which is undesirable in many migraine patients. Rimegepant is essentially weight-neutral, simplifying chronic management. In patients with multiple sclerosis, fibromyalgia, irritable bowel syndrome, and other comorbid pain syndromes that frequently overlap with migraine, rimegepant can be used without exacerbating these conditions. The absence of anticholinergic burden also makes it suitable for elderly patients in whom drugs like amitriptyline would raise the risk of falls, urinary retention, and cognitive impairment.

In patients undergoing surgery or other procedures, no specific perioperative precautions are needed for rimegepant, though clinicians should remain aware of the drug's CYP3A4 metabolism when prescribing perioperative antibiotics, antifungals, or analgesics. The drug does not affect platelet function, coagulation, or hemodynamics, so it does not need to be held before most procedures.

FAQ Section

Patients frequently ask whether rimegepant can be combined with their existing preventive medications. The answer is generally yes — rimegepant can be layered on top of beta-blockers, anticonvulsants, antidepressants, or onabotulinum toxin without dosing conflicts, provided that no strong CYP3A4 modulators are involved. The lack of pharmacodynamic overlap with these older preventives means that combining them is often a reasonable strategy in patients with partial responses.

Patients often also ask whether they will need to take rimegepant indefinitely. Many clinicians evaluate preventive efficacy after three to six months and consider tapering or holiday periods in patients who achieve sustained reductions in migraine frequency. Some patients are able to discontinue rimegepant after a year of stable improvement and remain in remission, while others require ongoing therapy. Migraine is a chronic, relapsing-remitting disorder, and the natural history varies considerably between individuals.

Another frequent question is how rimegepant compares to ubrogepant, the other oral gepant approved for acute migraine treatment. Both share the same mechanism of action and have generally comparable efficacy in trials, but rimegepant has the unique advantage of an FDA-approved preventive indication and the orally disintegrating tablet formulation. Ubrogepant is available only as a conventional swallow tablet and is indicated only for acute treatment. Choice between the two often comes down to insurance coverage, patient preference for formulation, and whether prevention is also a goal.

Patients also ask about the relationship between rimegepant and the injectable CGRP monoclonal antibodies such as erenumab, galcanezumab, fremanezumab, and eptinezumab. The monoclonal antibodies are large protein drugs administered by subcutaneous or intravenous injection at monthly or quarterly intervals; they bind either to CGRP itself (the ligand) or to its receptor. Rimegepant is a small oral molecule with a short half-life that binds to the same receptor. The two classes share mechanism but differ profoundly in pharmacokinetics, route of administration, and cost. They can be combined in selected patients, though long-term safety of combination has not been definitively established.

Many patients ask about cost: rimegepant is a branded specialty medication and tends to be expensive without insurance coverage. Manufacturer copay assistance programs and patient assistance foundations can substantially lower out-of-pocket costs for eligible patients. Healthcare providers should help patients navigate prior authorization requirements, which insurers commonly impose for newer migraine therapies. Many payers require trial and failure of at least two older oral preventive medications before approving rimegepant for prevention.

Patients with anxiety about taking medication during pregnancy planning often ask whether rimegepant should be stopped before attempting conception. While the human data are limited, animal studies have not shown major teratogenicity, and many headache specialists feel comfortable continuing rimegepant up to confirmation of pregnancy and then reassessing in collaboration with the patient's obstetrician. Migraine often improves during the second and third trimesters due to stable estrogen levels, which may reduce the need for any migraine-specific therapy during much of pregnancy.

The question of how soon a second dose can be taken if the first does not provide complete relief is also common. The current label permits only a single 75 milligram dose in 24 hours. If a migraine attack is not adequately controlled, patients may use a different class of acute medication — such as a triptan, an NSAID, or an antiemetic — for that attack, rather than redosing rimegepant. This restriction reflects the lack of safety and efficacy data for repeated dosing within 24 hours.

Finally, patients sometimes ask whether rimegepant could lose effectiveness over time. There is no compelling evidence of tachyphylaxis or pharmacodynamic tolerance to rimegepant. In long-term extension studies, the magnitude of benefit was generally maintained or even increased modestly with continued treatment. This durability of response represents another favorable feature of the gepant class.

In summary, rimegepant represents a meaningful advance in migraine treatment, offering a single oral medication that can be used both for acute attacks and for prevention of episodic migraine, with a tolerability and safety profile that is notably benign compared to many older therapies. Its lack of vasoconstrictor activity, low risk of medication-overuse headache, and convenient orally disintegrating tablet formulation have together established it as a first- or second-line option for many patients with migraine — and have helped move the field of headache medicine toward truly mechanism-based therapy. As clinical experience continues to accumulate and ongoing studies explore its role in chronic migraine, pediatric populations, and combination therapy with monoclonal antibodies, rimegepant's place in the migraine treatment armamentarium is likely to continue evolving. For now, it stands as one of the most important pharmacological advances in headache medicine in the past several decades.